Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations

ConclusionsNeoadjuvant versus adjuvant with standard anthracycline- and taxane-containing regimens results in similar disease-free survival and overall survival among patients with stage I and II triple-negative breast cancer regardless of BRCA status. Further studies are needed to evaluate whether similar results are observed with newer agents.

http://link.springer.com/10.1007/s10549-018-4727-9

Source: Breast Cancer Research and Treatment - February 22, 2018 Category: Cancer & Oncology Source Type: research